A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus

Edson S Brown, Alexandra Kulikova, Erin A Van Enkevort, Alyson K Nakamura, Elena Ivleva, Nicholas J. Tustison, Jared Roberts, Michael A. Yassa, Changho Choi, Alan Frol, David A Khan, Miguel A Vazquez, Traci Holmes, Kendra Malone

Research output: Contribution to journalArticle

Abstract

Preclinical and clinical research indicates that excess corticosteroid is associated with adverse effects on the hippocampus. Animal model data suggest that N-methyl-D-aspartate (NMDA) receptor antagonists may block corticosteroid effect on the hippocampus. This translational clinical trial investigated the effect of memantine vs. placebo on hippocampal subfield volume in humans receiving chronic corticosteroid therapy. Men and women (N = 46) receiving chronic prescription corticosteroid therapy were randomized to memantine or placebo in a double-blind, crossover design (two 24-week treatment periods, separated by a 4-week washout) for 52 weeks. Structural magnetic resonance imaging was obtained at baseline and after each treatment. Data were analyzed using repeated measures analysis of variance. Mean corticosteroid dose was 7.69 ± 6.41 mg/day and mean duration 4.90 ± 5.61 years. Controlling for baseline volumes, the left DG/CA3 region was significantly larger following memantine than placebo (p =.011). The findings suggest that an NMDA receptor antagonist attenuates corticosteroid effect in the same hippocampal subfields in humans as in animal models. This finding has both mechanistic and clinical implications. Attenuation of the effect of corticosteroids on the human DG/CA3 region implicates the NMDA receptor in human hippocampal volume losses with corticosteroids. In addition, by suggesting a drug class that may, at least in part, block the effects of corticosteroids on the human DG/CA3 subfield, these results may have clinical relevance for people receiving prescription corticosteroids, as well as to those with cortisol elevations due to medical or psychiatric conditions.

Original languageEnglish (US)
JournalNeuropsychopharmacology
DOIs
StatePublished - Jan 1 2019

Fingerprint

N-Methyl-D-Aspartate Receptors
Hippocampus
Adrenal Cortex Hormones
Memantine
Placebos
Prescriptions
Animal Models
Therapeutics
Cross-Over Studies
Psychiatry
Hydrocortisone
Analysis of Variance
Magnetic Resonance Imaging
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus. / Brown, Edson S; Kulikova, Alexandra; Van Enkevort, Erin A; Nakamura, Alyson K; Ivleva, Elena; Tustison, Nicholas J.; Roberts, Jared; Yassa, Michael A.; Choi, Changho; Frol, Alan; Khan, David A; Vazquez, Miguel A; Holmes, Traci; Malone, Kendra.

In: Neuropsychopharmacology, 01.01.2019.

Research output: Contribution to journalArticle

@article{8b0dacecee61482b9735e0cff61c2af2,
title = "A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus",
abstract = "Preclinical and clinical research indicates that excess corticosteroid is associated with adverse effects on the hippocampus. Animal model data suggest that N-methyl-D-aspartate (NMDA) receptor antagonists may block corticosteroid effect on the hippocampus. This translational clinical trial investigated the effect of memantine vs. placebo on hippocampal subfield volume in humans receiving chronic corticosteroid therapy. Men and women (N = 46) receiving chronic prescription corticosteroid therapy were randomized to memantine or placebo in a double-blind, crossover design (two 24-week treatment periods, separated by a 4-week washout) for 52 weeks. Structural magnetic resonance imaging was obtained at baseline and after each treatment. Data were analyzed using repeated measures analysis of variance. Mean corticosteroid dose was 7.69 ± 6.41 mg/day and mean duration 4.90 ± 5.61 years. Controlling for baseline volumes, the left DG/CA3 region was significantly larger following memantine than placebo (p =.011). The findings suggest that an NMDA receptor antagonist attenuates corticosteroid effect in the same hippocampal subfields in humans as in animal models. This finding has both mechanistic and clinical implications. Attenuation of the effect of corticosteroids on the human DG/CA3 region implicates the NMDA receptor in human hippocampal volume losses with corticosteroids. In addition, by suggesting a drug class that may, at least in part, block the effects of corticosteroids on the human DG/CA3 subfield, these results may have clinical relevance for people receiving prescription corticosteroids, as well as to those with cortisol elevations due to medical or psychiatric conditions.",
author = "Brown, {Edson S} and Alexandra Kulikova and {Van Enkevort}, {Erin A} and Nakamura, {Alyson K} and Elena Ivleva and Tustison, {Nicholas J.} and Jared Roberts and Yassa, {Michael A.} and Changho Choi and Alan Frol and Khan, {David A} and Vazquez, {Miguel A} and Traci Holmes and Kendra Malone",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41386-019-0430-8",
language = "English (US)",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A randomized trial of an NMDA receptor antagonist for reversing corticosteroid effects on the human hippocampus

AU - Brown, Edson S

AU - Kulikova, Alexandra

AU - Van Enkevort, Erin A

AU - Nakamura, Alyson K

AU - Ivleva, Elena

AU - Tustison, Nicholas J.

AU - Roberts, Jared

AU - Yassa, Michael A.

AU - Choi, Changho

AU - Frol, Alan

AU - Khan, David A

AU - Vazquez, Miguel A

AU - Holmes, Traci

AU - Malone, Kendra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Preclinical and clinical research indicates that excess corticosteroid is associated with adverse effects on the hippocampus. Animal model data suggest that N-methyl-D-aspartate (NMDA) receptor antagonists may block corticosteroid effect on the hippocampus. This translational clinical trial investigated the effect of memantine vs. placebo on hippocampal subfield volume in humans receiving chronic corticosteroid therapy. Men and women (N = 46) receiving chronic prescription corticosteroid therapy were randomized to memantine or placebo in a double-blind, crossover design (two 24-week treatment periods, separated by a 4-week washout) for 52 weeks. Structural magnetic resonance imaging was obtained at baseline and after each treatment. Data were analyzed using repeated measures analysis of variance. Mean corticosteroid dose was 7.69 ± 6.41 mg/day and mean duration 4.90 ± 5.61 years. Controlling for baseline volumes, the left DG/CA3 region was significantly larger following memantine than placebo (p =.011). The findings suggest that an NMDA receptor antagonist attenuates corticosteroid effect in the same hippocampal subfields in humans as in animal models. This finding has both mechanistic and clinical implications. Attenuation of the effect of corticosteroids on the human DG/CA3 region implicates the NMDA receptor in human hippocampal volume losses with corticosteroids. In addition, by suggesting a drug class that may, at least in part, block the effects of corticosteroids on the human DG/CA3 subfield, these results may have clinical relevance for people receiving prescription corticosteroids, as well as to those with cortisol elevations due to medical or psychiatric conditions.

AB - Preclinical and clinical research indicates that excess corticosteroid is associated with adverse effects on the hippocampus. Animal model data suggest that N-methyl-D-aspartate (NMDA) receptor antagonists may block corticosteroid effect on the hippocampus. This translational clinical trial investigated the effect of memantine vs. placebo on hippocampal subfield volume in humans receiving chronic corticosteroid therapy. Men and women (N = 46) receiving chronic prescription corticosteroid therapy were randomized to memantine or placebo in a double-blind, crossover design (two 24-week treatment periods, separated by a 4-week washout) for 52 weeks. Structural magnetic resonance imaging was obtained at baseline and after each treatment. Data were analyzed using repeated measures analysis of variance. Mean corticosteroid dose was 7.69 ± 6.41 mg/day and mean duration 4.90 ± 5.61 years. Controlling for baseline volumes, the left DG/CA3 region was significantly larger following memantine than placebo (p =.011). The findings suggest that an NMDA receptor antagonist attenuates corticosteroid effect in the same hippocampal subfields in humans as in animal models. This finding has both mechanistic and clinical implications. Attenuation of the effect of corticosteroids on the human DG/CA3 region implicates the NMDA receptor in human hippocampal volume losses with corticosteroids. In addition, by suggesting a drug class that may, at least in part, block the effects of corticosteroids on the human DG/CA3 subfield, these results may have clinical relevance for people receiving prescription corticosteroids, as well as to those with cortisol elevations due to medical or psychiatric conditions.

UR - http://www.scopus.com/inward/record.url?scp=85067700415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067700415&partnerID=8YFLogxK

U2 - 10.1038/s41386-019-0430-8

DO - 10.1038/s41386-019-0430-8

M3 - Article

C2 - 31181564

AN - SCOPUS:85067700415

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -